✦ LIBER ✦

61 TREATMENT WITH SOFOSBUVIR + RIBAVIRIN FOR 12 WEEKS ACHIEVES SVR12 OF 78% IN GT2/3 INTERFERON-INELIGIBLE, -INTOLERANT, OR -UNWILLING PATIENTS: RESULTS OF THE PHASE 3 POSITRON TRIAL

✍ Scribed by Jacobson, I.; Yoshida, E.M.; Sulkowski, M.; Nelson, D.R.; Svarovskaia, E.; An, D.; McNally, J.; Brainard, D.M.; Symonds, W.T.; McHutchison, J.G.; Pianko, S.; Kowdley, K.V.

Book ID: 123181599
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 60 KB
Volume: 58
Category: Article
ISSN: 0168-8278
DOI: 10.1016/S0168-8278(13)60063-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

6 ALL ORAL THERAPY WITH SOFOSBUVIR + RIB

6 ALL ORAL THERAPY WITH SOFOSBUVIR + RIBAVIRIN FOR 12 OR 16 WEEKS IN TREATMENT EXPERIENCED GT2/3 HCV-INFECTED PATIENTS: RESULTS OF THE PHASE 3 FUSION TRIAL

✍ Nelson, D.R.; Feld, J.; Kowdley, K.V.; Al-Assi, M.T.; Lin, M.; Mo, H.; McNally, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 74 KB

5 PHASE 3 RANDOMIZED CONTROLLED TRIAL OF

5 PHASE 3 RANDOMIZED CONTROLLED TRIAL OF ALL-ORAL TREATMENT WITH SOFOSBUVIR + RIBAVIRIN FOR 12 WEEKS COMPARED TO 24 WEEKS OF PEG + RIBAVIRIN IN TREATMENT-NAÏVE GT2/3 HCV-INFECTED PATIENTS (FISSION)

✍ Gane, E.; Lawitz, E.; Rodriguez-Torres, M.; Gordon, S.; Dvory-Sobol, H.; Arterbu 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 58 KB